| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to a novel compound of formula I possessing PDE2 inhibitor properties. In formula I n n n n (i) R 1 and R 2 together with a nitrogen atom form azetidin-1-yl; (ii) R 3 is H or C 1-4 alkyl; (iii) R 4 is phenyl, optionally substituted with one or more groups selected from C 1-4 alkyl, C 1-4 alkoxy and halogen C 1-4 alkyl; (iv) R 6 is H or C 1-4 alkyl. Compound can be in free form or in form of a pharmaceutically acceptable salt. Preferred compounds are compounds selected from group comprising 7-(azetidin-1-yl)-3-methyl-1-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-methoxy-2-methylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-cyclopropylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine; 7-(azetidin-1-yl)-1-(5-(4-ethylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-1H-pyrazolo[4,3-d]pyrimidine. n EFFECT: compound can be used in treating a disease, disorder or condition mediated PDE2, such as anxiety, depression, autism spectrum disorder, schizophrenia, anxiety and/or depression in autistic and/or schizophrenic patients, and cognitive disorders associated with schizophrenia or dementia, and so forth. n 10 cl, 1 dwg, 8 ex |